Next Article in Journal
Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges
Next Article in Special Issue
Advanced Blood–Brain Barrier Drug Delivery
Previous Article in Journal
Recent Progress on Hyaluronan-Based Products for Wound Healing Applications
Previous Article in Special Issue
Efficacy and Safety of a Brain-Penetrant Biologic TNF-α Inhibitor in Aged APP/PS1 Mice
 
 
Review
Peer-Review Record

Blood–Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles

Pharmaceutics 2022, 14(10), 2237; https://doi.org/10.3390/pharmaceutics14102237
by Maj Schneider Thomsen 1, Kasper Bendix Johnsen 1,2,3, Krzysztof Kucharz 4, Martin Lauritzen 4 and Torben Moos 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Pharmaceutics 2022, 14(10), 2237; https://doi.org/10.3390/pharmaceutics14102237
Submission received: 24 September 2022 / Revised: 14 October 2022 / Accepted: 14 October 2022 / Published: 19 October 2022
(This article belongs to the Special Issue Advanced Blood-Brain Barrier Drug Delivery)

Round 1

Reviewer 1 Report

The document is very interesting, actual and well written, however it is not clear what type of document it is (review or book chapter). If it is a review, the title should mention  it . In this case it may be a narrative review, so the search engines (data bases) must be named, as well as the time period (years) and the words/sentences used to do the search. That information should complement what was written from line 72 to 77.

 

 

 Some minor suggestions:

26: “ CSF, cerebrospinal fluid barrier” correct to cerebrospinal fluid (as in line 43)

94: correct “superseded “ to increased ??

157: correct “being many folds higher” to “being many times higher”

176: Correct/rephrase “However, the internalization did guarantee successful passage across the endothelium.”

179: Correct/rephrase “This observation was explained by antibodies forming covalent binding to the transferrin receptors sufficiently strong to prevent the antibodies from detaching from the receptor” Are there week covalent binding?????

204: Correct “Often studies determine” to “several/many….”

246: “as earlier studies” or “although earlier studies”???

300: Correct “Although been” to “Despite being”

462: remove “pathology” or consider pathological conditions? Or unhealthy conditions?

472: correct/rephrase “in the areas surrounding areas with central pathology” to “in the surrounding areas of a central pathology”???

491: correct “necessitates” to “requires”

Author Response

Reviewer I

Replies to Reviewer I

 

  • It is now indicated in the top header that the manuscript is a review paper. We have based the review on the most pertinent papers published in the literature using a broad search.

 

  • We have included virtually all the minor suggestions made by Reviewer I and appreciate these suggestions.

Reviewer 2 Report


Comments for author File: Comments.pdf

Author Response

Reviewer II

Replies to Reviewer I

  • We politely refrain from including more references on LRP-1 for BBB targeting: We have already included three references, and most importantly we have included two studies that both failed to prove evidences of LRP-1 targeting for BBB transport being it antibodies directed to LRP-1 or nanoparticles conjugated with LRP-1 ligands. Therefore, we find it justified what we have already written in the manuscript. The suggested references made by reviewer I do not include evidences of BBB transport at the morphological level to clearly determine the presence of particles inside the brain, and they did not include brain capillary purification experiments to separate the capillaries form the remaining brain tissue.

 

  • The reviewer comments on the use of transferrin receptor-targeting peptides: We have included what we find the most relevant for BBB transport, and this is in fact the only evidence published so far, we are including. So, we are in fact already including the relevant literature.

 

  • We have revised the manuscript for mistaken punctuations.

 

Back to TopTop